STONY BROOK, N.Y., January 10, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the “facility”) within its Stony Brook, New York, headquarters and readiness to accept orders [...]
STONY BROOK, N.Y. January 8, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results. [...]
STONY BROOK, N.Y., December 18, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the [...]
STONY BROOK, N.Y. – December 17, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. An update on the buildout of the Company’s GMP manufacturing facility [...]
STONY BROOK, N.Y. – December 16, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024. The Company will [...]
STONY BROOK, N.Y. October 30, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the pricing of a registered direct offering and concurrent private placement with gross proceeds to the Company expected to be approximately $6.5 million before deducting placement agent fees [...]
STONY BROOK, N.Y., October 15, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president and chief executive officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit. Maxim Group LLC is presenting the virtual summit [...]
STONY BROOK, N.Y., September 18, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on September 17, 2024, it received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), informing the Company that it has regained compliance with [...]
STONY BROOK, N.Y. September 17, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week: 3rd Annual mRNA Process Development & Manufacturing Summit – members of Applied DNA’s Biotherapeutics Sales and Business Development teams (collectively [...]